Low-potassium dextran solution ameliorates reperfusion injury of the lung and protects surfactant function  by Strüber, Martin et al.
Objective: This study was designed to compare the effect of lung preserva-
tion with low-potassium dextran solution and Euro-Collins solution on
reperfusion injury and surfactant function by using an in situ model of warm
ischemia.
Methods: The left lungs of 6 minipigs were selectively perfused with Euro-
Collins solution. In an additional 6 animals low-potassium dextran solution
was used for flush perfusion. After 90 minutes of warm ischemia, the lungs
were reperfused, and the contralateral pulmonary artery and bronchus were
clamped. Hemodynamic and respiratory measurements were obtained for 7
hours of reperfusion. Surface tension of bronchoalveolar lavage and surfac-
tant small and large aggregates were determined before perfusion (right
lung) and after 2 hours of reperfusion (left lung).
Results: In the group receiving Euro-Collins solution, right heart failure
developed within 215 ± 39 minutes of reperfusion. An increase in minimal
surface tension (P = .03), surfactant small aggregates/large aggregates ratio
(P = .003), and bronchoalveolar lavage protein content (P = .012) were
found after 2 hours of reperfusion. In the group receiving low-potassium
dextran solution, all minipigs survived (P = .0001). Dynamic lung compli-
ance (P = .034) and oxygen tension/inspired oxygen fraction ratios were
higher (P = .0001). Lung water content was lower (P = .049). The increase
of minimal surface tension (P = .02) and bronchoalveolar lavage protein con-
centration (P = .015) were significantly less.
Conclusion: Preservation of the lung with Euro-Collins solution leads to a
reduction of physical surfactant function during reperfusion. Low-potassium
dextran solution protects surfactant function and metabolism, thereby reducing
reperfusion injury of the lung.  (J Thorac Cardiovasc Surg 2000;120:566-72)
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symptoms range from mild reduction of compliance of
the lung to failure of the graft. The requirement of
extracorporeal support was reported in 7.4% of 215
recipients after lung transplantation.3 Numerous studies
have been undertaken to elucidate the pathophysiology
and to improve function of the reperfused graft. One of
the findings is the importance of endothelial and alveo-
P ulmonary allograft reperfusion injury remains a sig-nificant and common problem in clinical lung trans-
plantation. Perioperative mortality still is in the range of
10% to 15%, and reperfusion injury is one of the most
frequent causes of early death.1 The incidence of reper-
fusion injury has been reported to range from 20% to
40% in different lung transplant programs.2 Clinical
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to 5 minutes for a total volume of 40 mL/kg. Thereafter, the
incisions of the pulmonary veins were closed with running 5-0
Prolene sutures (Ethicon, Inc, Somerville, NJ). No interval of
cold storage of the left lung was used. After a warm ischemic
time of 90 minutes, the clamps were taken off the left atrium.
The perfusion cannulas were removed so that reperfusion of
the left lung was initiated. After 10 minutes of reperfusion,
the right pulmonary artery was clamped, as was the main
right bronchus. Both umbilical tapes were tied. During the
reperfusion period, the chest was temporarily closed, and
external warming was applied to maintain body and left lung
temperatures of 36.0°C to 37.0°C. Inotropic support to miti-
gate the effects of right heart insufficiency was administered
(adrenaline infusion up to 0.5 µg · kg–1 · min–1) when systolic
arterial pressure decreased below 60 mm Hg. Experiments
were terminated by means of a pentobarbital overdose after 7
hours of reperfusion or when systolic arterial pressure fell
below 40 mm Hg despite inotropic support. Thereafter, a
large specimen of the left lower lobe was taken for measure-
ment of lung water content.
Measurements of lung function. In all experiments, atrial
as well as systemic (carotid) arterial and pulmonary arterial
pressures were recorded online. Dynamic lung compliance
(C = Vt/[Peip - Peep], where Vt = tidal volume, Peip = positive
end-inspiratory pressure, and P
eep = positive end-expiratory
pressure) was monitored continuously with a modified venti-
lator (Dräger, Lübeck, Germany). Arterial blood gases were
analyzed after placement of catheters and every 30 minutes
during reperfusion. At this interval, pulmonary vascular resis-
tance (PVR) was calculated after measurement of cardiac
output with the thermodilution catheter (COM2 cardiac out-
put computer, Baxter).
Surfactant analysis. Bronchoalveolar lavage (BAL) fluid
was obtained from the right lower lobe in all experiments
after catheter placement by means of 100 mL of saline solu-
tion. A second BAL was performed after 2 hours of reperfu-
sion of the left lower lobe. The lavage fluid was immediately
centrifuged at 270g, and the cell-free supernatant was frozen
at –80°C. A surfactant pellet was resuspended in saline solu-
tion supplemented with 1.5 mmol/L calcium chloride. Pellet
and supernatant were separated at 27,000g for 30 minutes.
Protein and phospholipid content were determined according
to the method of Bartlett.11 Small and large aggregates were
separated, and their weight was expressed as a small/large
aggregates quotient. Surfactant function was determined by
means of a pulsating bubble surfactometer (Electronetics,
Buffalo, NY) according to the technique described by
Enhornig12: 40 µL of large aggregate suspension, which had
been adjusted to a phospholipid concentration of 1 mg/mL,
was filled into the sample chamber. The surface tension at
minimal bubble size (γ
min) was obtained after 5 minutes of
bubble pulsation at a rate of 20 cycles/min and a temperature
of 37°C. Before bubble pulsation was started, the initial sur-
face tension after bubble formation was measured, and the
adsorption rate was determined as surface tension 10 seconds
after formation of a bubble. All analog data were digitalized
and recorded by a personal computer.
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lar type II cell integrity after transplantation.4 It has
been shown earlier that flush perfusion of the lung with
Euro-Collins (EC) solution, which still is the most
common preservation technique, leads to impairment
of endothelial function.5 However, low-potassium dex-
tran (LPD) solution was found to be superior to EC
solution regarding preservation of endothelial func-
tion.6 In addition, a comparison of an extracellular
preservation solution, such as LPD solution, with the
currently used solution of intracellular ion composition
(EC solution) revealed less cytotoxicity and improved
metabolic activity of type II pneumocytes after preser-
vation with LPD solution.7 In lungs preserved with EC
solution, reduction of surfactant activity was found in
experimental lung transplantation.8 Supplementation
with surfactant preparations has improved graft func-
tion in the reperfusion period after experimental9 and,
in isolated cases, clinical lung transplantation.10
This study was designed to compare lung function,
surfactant activity, and metabolism after preservation
either with EC or LPD solution during a reperfusion
period.
Methods
Experimental groups. To compare the effect of 2 different
preservation solutions, 12 minipigs were randomized into 2
groups of 6 animals each. In the first group, preservation was
performed with EC solution, and in the second group, LPD
solution was used.
Surgical preparation. Female minipigs (22-30 kg) were
anesthetized with sodium pentobarbital (10 mg/kg) and fen-
tanyl (1 µg/kg), followed by fentanyl infusion at a rate of 1 µg
· kg–1 · h–1. The animals were intubated and ventilated with
50% oxygen (inspiratory/expiratory ratio, 1:1; positive end-
expiratory pressure, 5 mm Hg) in a pressure-controlled mode
(ventilatory cycles, 10/min; maximum inspiratory pressure,
20 mm Hg). A Swan-Ganz catheter (7.5F; Baxter Healthcare
Corporation, Irvine, Calif) and a catheter to monitor arterial
pressure were placed into the right carotid artery and internal
jugular vein, respectively. A left thoracotomy in the fifth
intercostal space was performed. The pericardium was
opened. A catheter for measurement of pressure was placed
into the left atrium. The left pulmonary artery, as well as the
tracheal bifurcation and the pulmonary veins, were dissected.
Umbilical tapes were applied to the right and left pulmonary
arteries and the right main bronchus. Heparin (3 mg/kg) was
administered intravenously. A catheter to infuse preservation
solution was inserted through the main pulmonary artery into
the left main pulmonary artery and stabilized there by tight-
ening of the umbilical tape. A clamp was placed onto the left
atrium so as to close the left pulmonary veins. The upper and
lower pulmonary veins were incised. Ventilation was contin-
ued, and cold (4°C) preservation solution was then infused
into the left pulmonary artery. The left lung was flushed for 3
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Lung water content. Specimens of the left lower lobe
were obtained after termination of the experiment. Wet and
dry weight were measured, and water content was expressed
as a percentage of wet weight.
Animal care. All animals received humane care in compli-
ance with the “Principles of Laboratory Animal Care” for-
mulated by the National Society for Medical Research and
the “Guide for the Care and Use of Laboratory Animals” pre-
pared by the National Academy of Sciences and published by
the National Institute of Health (National Institutes of Health
publication No. 80-23, revised 1985).
Statistical analysis. All data are expressed as means ± SE.
Intergroup analysis of continuous data were performed from
0.5 to 2.0 hours of reperfusion by repeated-measures analysis
of variance. For data without repeated measurement, 1-way
analysis of variance was applied. All data were analyzed with
the Statistical Program of Social Sciences (SPSS for MS
Windows version 6.1, SPSS, Inc, Chicago, Ill).
Results
Right heart failure developed within 3.58 ± 0.4 hours
of reperfusion (95% confidence interval, 2.81-4.36) in
the group receiving EC solution (Fig 1). All animals
required inotropic support after clamping of the right
pulmonary artery throughout the reperfusion period.
Three minipigs died within 3.5 hours of reperfusion.
No animal survived the observation period of 7 hours.
During the first 2 hours of reperfusion, a decrease in
oxygen tension/inspired oxygen fraction (PO2/FIO2)
from 558 ± 33 to 227 ± 85 mm Hg (Fig 2) was found.
After clamping of the right bronchus, dynamic compli-
ance declined (Fig 3) from 21.7 ± 0.9 to 11.3 ± 2.5
mL/mm Hg and remained in that range for the reperfu-
sion period. PVR increased after clamping of the right
lung from 330 ± 77 dynes · s–1 · cm–3 to 648 ± 102
dynes · s–1 · cm–3. A further increase was found after 60
minutes of reperfusion (961 ± 133 dynes · s–1 · cm–3).
Thereafter, PVR remained stable until the onset of right
heart failure, when high PVR was calculated at cardiac
outputs of less than 0.5 L/min (Fig 4). 
In the group receiving LPD solution, all animals
survived the observation period of 7 hours (P =
.0001). All minipigs of the LPD group received
inotropic support for 30 to 60 minutes after clamping
of the pulmonary artery. No inotropic agents were
required thereafter. PO2/FIO2 dropped from 585 ± 57
mm Hg at the onset of reperfusion to 382 ± 85 mm
Hg after 2 hours and 290 ± 79 mm Hg after 7 hours.
In comparison with the EC group, the oxygenation
index was significantly higher in the LPD group (P =
.034). Dynamic compliance of the LPD
solution–treated minipigs declined from 25.3 ± 2.2 to
18.7 ± 1.5 mL/mm Hg after clamping and to 17 ± 1.0
mL/mm Hg after 7 hours. Compliance (Fig 3) was
higher compared with that found in the EC group (P
= .0005). In the LPD group, PVR rose similar to the
EC solution–treated animals to 928 ± 178 dynes · s–1
Fig 1. Survival after reperfusion of the left lung and clamp-
ing of the right lung in percentage of animals per group.
Fig 2. PO2/FIO2 of lungs preserved with LPD and EC solution
before flush perfusion (basal) and after 0.5 to 7 hours of
reperfusion with clamping of the contralateral lung.
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· cm–3 after clamping of the right pulmonary artery
and remained stable until termination of the experi-
ments (Fig 4).
Lung water content of the reperfused lung at termi-
nation of the experiment was 89.4% ± 0.9% in the EC
group. Because of longer survival, specimens of the
LPD group were obtained later. The lung water content
was significantly lower (80.6% ± 3.5%, P = .049).
Surfactant analysis. When comparing minimal sur-
face tension of the BAL fluid before ischemia (right
lung), after ischemia, and after 2 hours of reperfusion
(left lung) in the group receiving EC solution (Fig 5), a
remarkable increase was found after reperfusion.
Concomitant with this finding was a higher protein
content (Fig 6) and an increase of the ratio of surface
nonactive small aggregates and the active surface large
aggregates of the BAL fluid (Fig 7).
A similar pattern was observed for the group receiv-
ing LPD solution: minimal surface tension (Fig 5) did
increase after reperfusion, as did protein concentration
of the BAL fluid (Fig 6) and the small aggregates/large
aggregates ratio (Fig 7). Comparing with EC solu-
tion–perfused lungs, minimal surface tension of the
LPD group was comparable before ischemia but signif-
icantly lower after reperfusion (P = .02). In comparison
with the EC group, protein concentration in the LPD
group was similar before ischemia; however, signifi-
cantly lower levels were obtained after reperfusion 
(P = .015). The small aggregates/large aggregates ratio
was comparable in the 2 groups before ischemia. A 3-
fold increase after reperfusion was observed for the
LPD solution–perfused lungs (Fig 7). Higher small
aggregates/large aggregates ratios were found for the
EC group after reperfusion (P = .07).
In terms of phospholipid concentration of the lavage
fluid, 60.3 ± 5.64 µg/mL was found before ischemia in
the group receiving EC solution, and 74.95 ± 9.77
µg/mL was found in the minipigs receiving the LPD
solution (P = .3) The concentrations were 74.95 ± 8.84
µg/mL (EC solution) and 85.52 ± 18.1 µg/mL (LPD
solution, P = .6) after reperfusion.
Discussion
The introduction of flush perfusion with EC solution
allowed for clinical lung preservation up to 6 to 8
hours.13 It has been successfully applied for more than
a decade and has become the most often used preserva-
tion method of the lung. However, reperfusion injury
remains a significant problem in lungs preserved with
EC solution in the early post-transplantation period.14
The biochemical rationale of this solution of intracel-
lular ion composition lies in the reduction of potassium
leakage of the preserved cells, leading to less intracel-
lular edema.15 However, cytotoxicity of potassium was
found to impair endothelial cells,5 as well as type II
pneumocytes,7 of the lung. In this study of preserva-
Fig 3. Dynamic compliance of lungs preserved with LPD and
EC solution before flush perfusion (basal) and after 0.5 to 7
hours of reperfusion with clamping of the contralateral lung.
Fig 4. Pulmonary vascular resistance (PVR) of lungs pre-
served with LPD and EC solution before flush perfusion
(basal) and after 0.5 to 7 hours of reperfusion with clamping
of the contralateral lung.
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tion, warm ischemia, and reperfusion of the lung, lethal
reperfusion injury was induced in the EC solution
group. This was characterized by deteriorating lung
function and right heart failure independent of any
immunologic response to an allograft. Surfactant
analysis after 2 hours of reperfusion revealed a signifi-
cant increase of minimal surface tension and thus a
lack of adequate surfactant function. Concomitant with
this finding was a reduction of dynamic lung compli-
ance. In contrast, cardiopulmonary function remained
stable in the LPD solution group. Adequate surfactant
function was maintained in this group, as was demon-
strated by surfactant analysis after 2 hours of reperfu-
sion and stable dynamic lung compliance throughout
the experiment.
Limitations of this study are the use of warm
ischemia in contrast to cold ischemia in clinical lung
transplantation and the absence of immunologic
responses to an allograft. Compared with other prepa-
rations of isolated cells, ex vivo perfused organ models,
and allotransplantation models in small animals, the
use of our model has the advantage of a cardiopul-
monary circulation similar to that of human subjects.
Interactions of the pulmonary circulation and right
heart function resemble the clinical situation in single
lung transplantation. A further advantage of this model
is the avoidance of donor animals, thus reducing the
number of minipigs required by 50%. Short-term warm
ischemia develops very rapidly and induces severe
reperfusion injury at a reliable rate in EC solution–pre-
served lungs, as was known from earlier experiments
with this model.16 This induction of lung failure resem-
bles clinical graft failure after lung transplantation in
reduction of compliance, gas exchange, and increase of
PVR. Whether the impairment of surfactant function
follows the same pattern is likely but not verified.
Plasma proteins, such as albumin and hemoglobin,
are widely known inhibitors of surfactant function.17
The loss of surfactant function in the EC solution group
is most certainly the result of inhibition caused by plas-
ma proteins leaking into the alveoli. This hypothesis is
supported by the findings of increased protein content
Fig 5. Minimal surface tension of BAL fluid in milli-
Newtons per meter, as determined with a bubble surfactome-
ter. Results are shown before flush perfusion of the right
lungs (basal) and after 2 hours of reperfusion of the left
lungs.
Fig 6. Protein concentration of BAL fluid in milligrams per
liter. Results are shown before flush perfusion of the right
lungs (basal) and after 2 hours of reperfusion of the left
lungs.
solutions used clinically for lung preservation, such as
EC solution or University of Wisconsin solution, are
high potassium–containing intracellular-type solutions.
Despite this fact, no clinical study was published
revealing superiority of these solutions when compared
with low-potassium extracellular-type solutions. A
body of evidence was established of the injurious
effects of high-potassium solutions on endothelial
cells, as well as epithelial cells. Because safe preserva-
tion of lungs with excellent pulmonary function was
demonstrated in a pig model23 of single lung transplan-
tation, our experiments revealing improved surfactant
function after ischemia and reperfusion, as well as
numerous other studies indicating improved preserva-
tion quality of LPD solution, suggest that clinical use
of LPD solution should be considered. It remains to be
shown by clinical data whether LPD solution does
indeed reduce reperfusion injury after clinical lung
transplantation and improve surfactant function. In
addition, further studies are required to reveal protec-
tive measures of surfactant function after lung trans-
plantation with respect to long-term graft function.
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of the BAL fluid after reperfusion and the increase of
the small aggregates/large aggregates ratio, indicating a
decrease of surface active large aggregates and an
increase of nonactive small aggregates. In contrast, in
the LPD solution group, protein content of the BAL
fluid did not increase during reperfusion, and the small
aggregates/large aggregates quotient did not rise.
Surfactant function remained stable in this group. In
addition, lung water content was significantly lower in
the LPD group than in the EC group at the end of the
experiments. These findings indicate a reduction of
lung edema formation caused by preservation with
LPD solution with less plasma protein leakage into the
alveolar space. Therefore, surfactant inhibition did not
occur to the same extent as in the EC group.
In human lung transplant recipients of EC solu-
tion–perfused grafts, severe impairment of biophysical
surfactant function was found, as well as an increase of
the small aggregates/large aggregates ratio18 in the
early postoperative course. This dysfunction may
account in part for an impairment of graft function. In
animal experiments,19,20 as well as in clinical cases,10
early postoperative graft dysfunction was successfully
improved by administration of surfactant preparations.
The question remains of whether the surfactant dys-
function of EC solution–perfused and transplanted
lungs is only attributable to an inactivation of surfactant
by plasma proteins or if surfactant generation is also
disturbed. Studies of isolated type II pneumocytes
revealed less cellular edema and less damage to the
nuclear membrane when stored in LPD solution com-
pared with University of Wisconsin solution, another
intracellular-type high-potassium solution.21 In addi-
tion, a higher metabolic activity of type II pneumocytes
was found when stored in LPD rather than in EC solu-
tion.7 This indirect evidence of a disturbed type II
pneumocyte function after EC solution storage is
strengthened by the fact that surfactant function did not
recover in the long-term follow-up after clinical lung
transplantation.18 However, the degree of vascular leak-
age of plasma proteins into the alveolar space may be
the most important mechanism of reduction of surfac-
tant function in the reperfusion period. In part, the vas-
cular leakage may be due to an impairment of endothe-
lial and smooth muscular function of the pulmonary
vessels. In an earlier study with the same model, a sim-
ilar improvement of lung function and surfactant activ-
ity was shown with the supplementation of a surfactant
preparation before reperfusion.22 However, with surfac-
tant administration, an increase of protein concentra-
tion of the BAL fluid after reperfusion could not be pre-
vented in lungs preserved in EC solution. Most
Fig 7. Small aggregates/large aggregates ratio of BAL fluid.
Results are shown before flush perfusion of the right lungs
(basal) and after 2 hours of reperfusion of the left lungs.
572 Strüber et al The Journal of Thoracic and
Cardiovascular Surgery
September 2000
R E F E R E N C E S
1. Cooper JD, Patterson GA, Trulock EP, the Washington University
Lung Transplant Group. Results of 131 consecutive single and
bilateral lung transplant recipients. J Thorac Cardiovasc Surg
1994;107:460-71.
2. Colquhoun IW, Kirk AJB, Au J, et al. Single flush perfusion with
modified Euro-Collins solution: experience in clinical lung
preservation. J Heart Lung Transplant 1992;11:S209-14.
3. Glassman JR, Keenan RJ, Fabrizio MC, et al. Extracorporeal
membrane oxygenation as an adjunct for primary graft failure in
adult lung transplant recipients. J Thorac Cardiovasc Surg
1995;110:723-7.
4. Novick RJ, Gehman KE, Ali IS, Lee J. Lung preservation: the
importance of endothelial and alveolar type II cell integrity. Ann
Thorac Surg 1996;62:302-14.
5. Strüber M, Ehlers KA, Nielsson FN, Miller VM, McGregor
CGA, Haverich A. Effect of lung preservation with Euro-Collins
and University of Wisconsin solution on endothelium dependent
relaxations. Ann Thorac Surg 1997;63:1428-35. 
6. Ingemansson R, Massa G, Pandita RK, Sjöberg T, Steen S.
Perfadex is superior to Euro-Collins Solution regarding 24 hour
preservation of vascular function. Ann Thorac Surg
1995;60:1210-4.
7. Maccherini M, Keshavjee SH, Slutsky AS, Patterson GA,
Edelson JD. The effect of low-potassium dextran versus Euro-
Collins solution for preservation of isolated type II pneumocytes.
Transplantation 1991;52:621-6.
8. Veldhuizen RAW, Lee J, Sandler D, et al. Alterations in pul-
monary surfactant composition and activity after experimental
lung transplantation. Am Rev Respir Dis 1993;148:208-15.
9. Novick RJ, Veldhouzen RAW, Possmeyer F, et al. Exogenous sur-
factant therapy in thirty-eight hour lung graft preservation for
transplantation. J Thorac Cardiovasc Surg 1994;108:259-68.
10. Strüber M, Cremer J, Harringer W, et al. Nebulized synthetic sur-
factant in reperfusion injury after single lung transplantation. J
Thorac Cardiovasc Surg 1995;110:563-4.
11. Bartlett GR. Phosphorus assay in column chromatography Biol
Chem 1959;234:466-8.
12. Enhornig G. Pulsating bubble technique for evaluating pul-
monary surfactant. J Appl Physiol 1977;43:198-203.
13. Haverich A, Scott WC, Jamieson SW. Twenty years of lung
preservation—a review. J Heart Transplant 1985;4:234-40.
14. Trulock E. Lung transplantation. Am J Respir Crit Care Med
1997;155:789-818.
15. Collins GM, Bravo-Shugarman M, Terasaki PI. Kidney preserva-
tion for transplantation: initial perfusion and 30 hours ice storage.
Lancet 1969;2:1219-22.
16. Strüber M, Harringer W, Ernst M, et al. Inhaled nitric oxide as a
prophylactic treatment against reperfusion injury of the lung.
Thorac Cardiovasc Surg 1999;47:179-82.
17. Fuchimukai T, Fujiwara T, Takahashi A, Enhorning G. Artificial
pulmonary surfactant inhibited by proteins. Appl J Physiol
1987;62:429-37.
18. Hohlfeld JM, Tiryaki E, Hamm H, et al. Pulmonary surfactant
activity is impaired in lung transplant recipients. Am J Respir Crit
Care Med 1998;158:706-12.
19. Novick R, MacDonald J, Veldhuizen R, et al. Evaluation of sur-
factant replacement treatment strategies after prolonged graft
storage in lung transplantation. Am J Respir Crit Care Med
1996;154:98-104.
20. Erasmus ME, Petersen AH, Hofstede G, et al. Surfactant treat-
ment before reperfusion improves immediate function of lung
transplants in rats. Am J Respir Crit Care Med 1996;153:665-70.
21. Carbognani, Rusca M, Solli P, et al. Pneumocytes type II ultra-
structural modifications after storage in preservation solutions for
transplantation. Eur Surg Res 1997;29:319-26.
22. Hohlfeld JM, Strüber M, Ahlf J, et al. Exogenous surfactant
improves survival and surfactant function in ischemia-reperfu-
sion injury in minipigs. Eur Respir J 1999;13:1037-43.
23. Steen S, Kimblad PO, Sjöberg T, Lindberg L, Ingemannsson R,
Massa G. Safe lung preservation for twenty hours with Perfadex.
Ann Thorac Surg 1994;57:450-7.
Timely
The Journal of Thoracic and Cardiovascular Surgery delivers the information you need now. Articles usually appear within four
months of acceptance.
